Questions and Answers from October 29 through November 1

FY 2016-2017 Funding Opportunity Announcement (FOA)
Zika Research Grant Initiative

If you submitted a question that does not appear here, we will be posting the answers to these questions on or around Monday, November 7, 2016.

1. **Is there a page limit for LOI?**

   The LOI is a fillable form, and as such, page limits do not apply. The form is available at [https://apps.orau.gov/FLDOH_Zika/Account/Login](https://apps.orau.gov/FLDOH_Zika/Account/Login). The only written section of the form is the general audience abstract. The length limit on this section is 3,500 characters.

2. **Is there a review after LOI?**

   The LOIs will be reviewed for completeness and applicants will be informed if there is an issue with their LOI that would disqualify them from progressing to the application stage.

3. **Do the character counts in the LOI and main grant application include spaces?**

   Yes, the character counts include spaces.

4. **What are we expected to write in “Zika Relatedness Statement”? Also, is “Health Impact” asking about the health impact of Zika virus on humans or health impact of our studies on Zika virus infection?**

   In the “Health Impact” statement you will need to provide a clear and concise description of how the proposed project impacts the health of Floridians. Health impact means the ability of the research to reduce the incidence, prevalence, and health effects of Zika. Please see the table on page 14 of the FOA for more information. The “Zika Relatedness” statement provides a clear explanation of how the project is related to Zika.

5. **Will researchers have access to samples obtained in the Florida Department of Health Zika surveillance activities?**
The Department is looking into the mechanism to make samples collected during our investigation and surveillance activities available to researchers (e.g., consent). At the moment, the Department is not making biological specimens or patient information available for research and will not be recruiting or enrolling study participants. We have developed a letter for mailing to individuals who test positive for Zika virus infection. The letter includes contact information for research studies in which they can participate. In the future, if you would like your study and contact information to be included in this letter, you will need to send the Department (research@flhealth.gov) a copy of the IRB approval from your institution, a brief description of your study, and answer the following questions:

What do you need from study participants?
Whom should the patient contact?